Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,828,706 papers from all fields of science
Search
Sign In
Create Free Account
PEGINTERFERON
Known as:
peginterferons
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
Drug Allergy
Hepatitis C, Chronic
Hepatitis, Autoimmune
Infant, Newborn
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis
N. Choudhary
,
Ajay Kumar
,
+5 authors
N. Saraf
Indian Journal of Gastroenterology
2017
Corpus ID: 12848898
IntroductionPatients with end-stage renal disease (ESRD) have poor treatment tolerance and outcome to interferon-based regimens…
Expand
2015
2015
Managing Diabetes and Liver Disease Association Guidelines (Consensus) Development
H. A. Khalek
,
B. Abass
,
Amany Abdel Maqsod
2015
Corpus ID: 41601672
2015
2015
Retreatment with peginterferon and ribavirin in chronic hepatitis C
YongMinJo
,
SungWookLee
,
+5 authors
JiyoungLee
2015
Corpus ID: 81954673
The development of boceprevir and telaprevir was a major step forward in the treatment of chronic hepatitis C.In addition,the…
Expand
2014
2014
Simeprevir approved for hepatitis C virus infection.
K. Traynor
American Journal of Health-System Pharmacy
2014
Corpus ID: 1122088
Janssen Therapeutics on November 22 announced the approval of simeprevir oral capsules as part of a combination regimen for the…
Expand
2014
2014
Sofosbuvir approved for chronic hepatitis C infection.
K. Traynor
American Journal of Health-System Pharmacy
2014
Corpus ID: 40330036
FDA and Gilead Sciences on December 6 announced the approval of sofosbuvir oral tablets as part of a regimen for the treatment of…
Expand
Review
2012
Review
2012
[Systematic review of new protease inhibitors interactions: telaprevir and boceprevir].
E. Izquierdo-García
,
I. Escobar-Rodríguez
Farmacia Hospitalaria
2012
Corpus ID: 196247754
INTRODUCTION The new protease inhibitors (PIs), telaprevir and boceprevir, with peginterferon and ribavirin, have increased the…
Expand
2011
2011
Telaprevir treatment (Incivek): Telaprevir in combination with peginterferon alfa and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease.
F. Staff
2011
Corpus ID: 73929573
New molecular entity: Telaprevir in combination with peginterferon alfa and ribavirin was FDA approved for the treatment of…
Expand
2010
2010
High Correlation Between Week 4 and Week 12 as the Definition for Null Response to Peginterferon alfa (PEG) Plus Ribavirin (R) Therapy: Results From the IDEAL Trial
F. Poordad
,
M. Sulkowski
,
+8 authors
C. Brass
2010
Corpus ID: 73807823
Background: The objective of this retrospective analysis was to investigate the correlation between HCV viral load declines at…
Expand
2009
2009
Benefits and Risks of Combination Therapy for Hepatitis
N. Terrault
2009
Corpus ID: 27828729
In successful antiviral therapy of hepatitis B, drug combinations, particularly combinations without cross-resistance, can delay…
Expand
2009
2009
Impact of early viral kinetics on pegylated interferon alpha 2b plus ribavirin therapy in Japanese patients with genotype 2 chronic hepatitis C
H. Nomura
,
Yugo Miyagi
,
H. Tanimoto
,
H. Ishibashi
Journal of Viral Hepatitis
2009
Corpus ID: 25726443
Summary. The recommended therapy for genotype‐2 chronic hepatitis C is a regimen of pegylated interferon alpha (peginterferon…
Expand